Christopher D. Watt, MD, PhD
Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Penn Medicine Provider
About me
- Associate Director, Molecular Pathology Laboratory
- Associate Professor of Clinical Pathology and Laboratory Medicine
My clinical expertise is in Molecular Pathology.
My education and training
- Medical School: University of Pennsylvania School of Medicine
- Residency: University of Pennsylvania Health System
- Fellowship: University of Pennsylvania Health System
Spoken languages
English
English
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
- Devoted Health Choice Giveback Pennsylvania (PPO)
- Devoted Health Choice Pennsylvania (PPO)
- Devoted Health Choice Plus Pennsylvania (PPO)
- Devoted Health Core Pennsylvania (HMO)
- Devoted Health Dual Plus Pennsylvania (HMO D-SNP)
- Devoted Health Giveback Pennsylvania (HMO)
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Pennsylvania Hospital: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Qualifications and experience
- Pathology - Molecular Genetic
- Pathology - Clinical
- American Medical Association, Member, National
- American Society for Clinical Pathology, Fellow Member, International
- Association for Molecular Pathology, Associate Member, International
- College of American Pathologists, Fellow Member, International
Treatments and conditions
Research
Publications
Bakas S, Sako C, Akbari H, Bilello M, Sotiras A, Shukla G, Rudie JD, Santamaría NF, Kazerooni AF, Pati S, Rathore S, Mamourian E, Ha SM, Parker W, Doshi J, Baid U, Bergman M, Binder ZA, Verma R, Lustig RA, Desai AS, Bagley SJ, Mourelatos Z, Morrissette J, Watt CD, Brem S, Wolf RL, Melhem ER, Nasrallah MP, Mohan S, O'Rourke DM, Davatzikos C The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics , Sci Data, 9(1): 2022
Nelson N, Priore S, Sondermann J, Herlihy S, Watt CD Evaluation of Positive Control Material for MGMT Promoter Methylation Studies , Journal of Molecular Diagnostics, 23(11): 2021,1618
Gentile C, Richard-Greenblatt M, Fink J, Elkan M, Harris RM, Van Deerlin VM, Glaser L, Watt CD, Herlihy SE A Practical Comparison of Seven Molecular SARS-CoV-2 Methods , The Journal of Molecular Diagnostics, 22(11): 2020,S33
Zhang Q, Orlando EJ, Wang HY, Bogusz AM, Liu X, Lacey SF, Strauser HT, Nunez-Cruz S, Nejati R, Zhang P, Brooks S, Watt CD, Melenhorst JJ, June CH, Schuster SJ, Wasik MA Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome , Blood, 136(17): 2020,1980-1983
Herlihy SE, Carlin A, Nasrallah NP, Watt CD and Van Deerlin VM Evaluation of a Targeted Realtime Assay for Rapid Identification of IDH1 and IDH2 Disease-Associated Variants in Brain Tumors , The Journal of Molecular Diagnostics, 21(6): 2019,1201
Garces S, Nelson N, Watt CD, and Priore S FLT3 Variants Near Codon 835: An Institutional Experience Comparing Rapid Restriction Digest Testing with Massively Parallel Sequencing. , The Journal of Molecular Diagnostics, 21(6): 2019,1230
McMahon C, Ferng T, Canaani J, Wang E, Morrissette J, Eastburn D, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater E, DeFilippis RA, Peretz C, McGary L, Deihimi S, Logan A, Luger S, Shah N, Carroll M, Smith C, and Perl A Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , Cancer Discovery, 9(8): 2019,1050-1063
Brown JT, Beldorth IJ, Laosinchai-Wolf W, Fahey ME, Jefferson KL, Ruskin AK, Roth JJ, Cai L, Watt CD, Press RD, Yang F, Hedges JB, and Andruss BF Analytical validation of a highly sensitive, multiplexed chronic myeloid leukemia monitoring system targeting BCR-ABL1 RNA. , The Journal of Molecular Diagnostics, 21(4): 2019,718-733
Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, Watt CD, Sukhadia S, Klinman E, Daber RD, Desai A, O’Rourke DM, and Morrissette JJD Molecular neuropathology in practice: Clinical profiling and integrative analysis of molecular alterations in glioblastoma. , Academic Pathology, 6: 2019,2374289519848353
McMahon CM, Canaani J, Rea B, Sargent R, Watt CD, Morrissette JJD, Carroll M, and Perl AE Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. , Blood Advances, 3(10): 2019,1581-1585